Adalimumab in Severe and Acute Sciatica

NCT ID: NCT00470509

Last Updated: 2019-04-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-05-31
• Study Completion Date: 2008-06-30

Brief Summary

The purpose of this study is to determine whether adalimumab (a TNF-alpha inhibitor) is effective in the treatment of severe and acute sciatica.

Detailed Description

Sciatica and low back pain are common problems that lead to major costs in Western countries. The presence of herniated disc is generally considered as the leading cause of sciatica. However, recent findings indicate that the presence of this mechanism is not sufficient to explain all the clinical signs of radiculopathy and that inflammatory mechanisms contribute also to the pathophysiology of sciatica. Indeed, herniated discs contain large amounts of tumor necrosis factor (TNF-alpha) which can induce acute and chronic inflammation and pain. It has recently been demonstrated that TNF-alpha inhibitors (infliximab or etanercept) were able to prevent the occurrence of pain in an experimental model of sciatica. In addition, two independent preliminary studies have shown that patients treated with TNF-alpha inhibitors had better evolution than an historical control group. This study has been designed to verify the hypothesis that TNF-alpha has a major role in human sciatica and that anti-TNF-alpha agents are interesting therapeutic approaches in severe sciatica.

Conditions

Sciatica

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Adalimumab

adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)

Group Type: EXPERIMENTAL

Adalimumab

Intervention Type: DRUG

2 subcutaneous injections on day 0 and 7

Placebo

2 placebo injections on day 0 and 7

Group Type: PLACEBO_COMPARATOR

Placebos

Intervention Type: DRUG

2 subcutaneous injections on day 0 and 7

Interventions

Adalimumab

2 subcutaneous injections on day 0 and 7

Intervention Type: DRUG

Placebos

2 subcutaneous injections on day 0 and 7

Intervention Type: DRUG

Other Intervention Names

Humira; placebo injection

Eligibility Criteria

Inclusion Criteria

1. Male or female patients older than 18

2. Episode of radicular pain in one lower limb for less than 12 weeks.

3. Medical evaluation requiring hospitalisation because of pain or functional handicap

4. Patients presenting a characteristic leg pain in the L3, L4, L5, or S1 territories plus at least one of the following: :

• positive straight-leg-raising test with an elevation of less than 70°
• positive femoral stretched
• clear clinical sign of nerve root involvement

• muscle strength deficiency or
• sensory disturbances in clear cut dermatome or
• lower limb reflex asymmetry.

5. Oswestry score greater than 50

6. If there is a past history of radicular pain involving the same nerve root, a 6 months interval free of leg pain is required.

7. A confirmed herniated disc on usual imaging techniques (CT scan or MRI) in the vicinity of the clinically involved nerve root that has been performed within the last 2 years.

8. Written informed consent

Exclusion Criteria

1. The presence of recent (<48 hours) severe muscle weakness (<3/5) or clinical signs of cauda equina compression, requiring immediate surgery.

• If surgical procedure is required but is denied, either because of surgeon's decision or because of patient's fully informed decision, then this patient could be included in the protocol.

2. Comorbidities such as :

• Coexisting infections (Chest X-ray will be performed to all patients and tuberculin skin test in case of doubt concerning a past history of tuberculous infection).
• Autoimmune disease (other than RA).
• History of cancer or malign lymphoproliferative disorders (unless the patient has been declared in remission for more than 5 years)
• History of demyelinating disorders.

3. Pregnancy.

4. History of intolerance to adalimumab or any of its ingredients

5. Previous participation in this clinical study.

6. Participation in another clinical study within 4 weeks prior to the start of or during this study.

7. Poor motivation or other emotional or intellectual problems that are likely to limit the ability of the patient to comply with the protocol requirements.

The investigators will also be allowed to exclude an individual patient from the study and remove the blinding in case of a superimposed infection or any severe side effect during the trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Geneva

OTHER

Sponsor Role: lead

Responsible Party

Stephane Genevay

Dr

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Stéphane Genevay, MD

Role: PRINCIPAL_INVESTIGATOR

Geneva University Hospital & Swiss Society of Rheumatology

Locations

Geneva University Hospital

Geneva, , Switzerland

Countries

Switzerland

References

Genevay S, Viatte S, Finckh A, Zufferey P, Balague F, Gabay C. Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Aug;62(8):2339-46. doi: 10.1002/art.27499.

Reference Type: DERIVED

PMID: 20506391 (View on PubMed)

Other Identifiers

ASAS

Identifier Type: -

Identifier Source: org_study_id